BIO.News Newsletter

The FDA approved updated COVID vaccines as COVID is surging, and we’re marking the one-year anniversary of Biden’s biomanufacturing executive order with a look at what more needs to be done. (566 words, 2 minutes, 49 seconds)

A new week begins with updates on COVID-19 (and possibly to the vaccines) and a boost for biofuels and biotech collaboration at the G20 in India. Plus, Congress is back to work with lots to do on a few BIO priorities. (498 words, 2 minutes, 29 seconds)

Happy Friday. We look at news from China on biotech crops plus what experts have been saying about drug price controls. (553 words, 2 minutes, 45 seconds)

BIO CEO Rachel King discussed price controls, investment opportunities, and much more on two new podcasts—here are a few takeaways. Plus, a long-term opportunity with short corn and news about COVID. (807 words, 4 minutes, 2 seconds)

A busy season of flu infections is projected, and ocean warming is also increasing attacks of flesh-eating bacteria. (531 words, 2 minutes, 36 seconds)

We’re back—and so’s the Senate. Here’s all the news you missed last week plus the launch of the new season of the I am BIO Podcast. (646 words, 3 minutes, 13 seconds)

There’s one more week of recess—and Good Day BIO will be taking a break next week before a busy fall. In the meantime, we have summer reading + a few stories you might have missed. We’ll see you on September 5. (659 words, 3 minutes, 17 seconds)

BIO will file an amicus brief today in the Amgen-Horizon Federal Trade Commission (FTC) case—we have the scoop, plus what immunocompromised patients need to know about the benefits of COVID vaccines. (541 words, 2 minutes, 42 seconds)

The federal government awarded $1.4 billion in grants to accelerate new COVID-19 technologies as new variants are causing concern—plus, as heat records become the “new normal,” what’s the role for biotech? (594 words, 2 minutes, 58 seconds)

“The Year of RSV” continues with FDA’s third RSV approval, and a new report highlights the economic value of California’s life sciences sector.